Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 80

1.

Phase I study of the novel Cdc2/CDK1 and AKT inhibitor terameprocol in patients with advanced leukemias.

Tibes R, McDonagh KT, Lekakis L, Bogenberger JM, Kim S, Frazer N, Mohrland S, Bassett D, Garcia R, Schroeder K, Shanmugam V, Carpten J, Hagelstrom RT, Beaudry C, Von Hoff D, Shea TC.

Invest New Drugs. 2015 Apr;33(2):389-96. doi: 10.1007/s10637-014-0198-y. Epub 2014 Dec 19.

PMID:
25523151
2.

Phase I study of MLN8237--investigational Aurora A kinase inhibitor--in relapsed/refractory multiple myeloma, non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Kelly KR, Shea TC, Goy A, Berdeja JG, Reeder CB, McDonagh KT, Zhou X, Danaee H, Liu H, Ecsedy JA, Niu H, Benaim E, Iyer SP.

Invest New Drugs. 2014 Jun;32(3):489-99. doi: 10.1007/s10637-013-0050-9. Epub 2013 Dec 20.

3.

Leadership succession planning: a governance imperative.

McDonagh KJ, Prybil L, Totten MK.

Trustee. 2013 Apr;66(4):15-8. No abstract available.

PMID:
23798287
4.

The reversal of inhibitors in congenital hemophilia.

DeFrates SR, McDonagh KT, Adams VR.

Pharmacotherapy. 2013 Feb;33(2):157-64. doi: 10.1002/phar.1173. Epub 2013 Jan 25. Review.

PMID:
23355059
5.

The leadership labyrinth: leveraging the talents of women to transform health care.

McDonagh KJ, Paris NM.

Nurs Adm Q. 2013 Jan-Mar;37(1):6-12. doi: 10.1097/NAQ.0b013e3182751327.

PMID:
23222748
6.

An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib.

Vij R, Siegel DS, Jagannath S, Jakubowiak AJ, Stewart AK, McDonagh K, Bahlis N, Belch A, Kunkel LA, Wear S, Wong AF, Wang M.

Br J Haematol. 2012 Sep;158(6):739-48. doi: 10.1111/j.1365-2141.2012.09232.x. Epub 2012 Jul 30.

PMID:
22845873
7.

The leadership labyrinth: career advancement for women.

McDonagh KJ, Paris NM.

Front Health Serv Manage. 2012 Summer;28(4):22-8. No abstract available.

PMID:
22787908
9.

An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma.

Vij R, Wang M, Kaufman JL, Lonial S, Jakubowiak AJ, Stewart AK, Kukreti V, Jagannath S, McDonagh KT, Alsina M, Bahlis NJ, Reu FJ, Gabrail NY, Belch A, Matous JV, Lee P, Rosen P, Sebag M, Vesole DH, Kunkel LA, Wear SM, Wong AF, Orlowski RZ, Siegel DS.

Blood. 2012 Jun 14;119(24):5661-70. doi: 10.1182/blood-2012-03-414359. Epub 2012 May 3.

10.

Progress on stem cell research towards the treatment of Parkinson's disease.

Gibson SA, Gao GD, McDonagh K, Shen S.

Stem Cell Res Ther. 2012 Apr 3;3(2):11. doi: 10.1186/scrt102. Review.

11.
12.

A framework for patient safety, part 2: resilience, the next frontier.

Blouin AS, McDonagh KJ.

J Nurs Adm. 2011 Nov;41(11):450-2. doi: 10.1097/NNA.0b013e3182346eae.

PMID:
22033313
13.

Framework for patient safety, part 1: culture as an imperative.

Blouin AS, McDonagh KJ.

J Nurs Adm. 2011 Oct;41(10):397-400. doi: 10.1097/NNA.0b013e31822edb4d.

PMID:
21934425
14.

The board's role in technology advancement.

McDonagh KJ.

Trustee. 2009 Sep;62(8):27, 32, 1.

PMID:
19960796
15.

Leadership in innovation: life beyond the hospital.

McDonagh KJ.

Nurs Adm Q. 2009 Oct-Dec;33(4):325-8. doi: 10.1097/NAQ.0b013e3181b9dd68.

PMID:
19893446
16.

Identifying grant funding: mentored career development and transition awards.

McDonagh KT.

Hematology Am Soc Hematol Educ Program. 2008:12-5. doi: 10.1182/asheducation-2008.1.12.

17.

Connecting governance culture and hospital performance improvement.

McDonagh KJ, Chenoweth J, Totten MK, Orlikoff JE.

Trustee. 2008 Apr;61(4):4 p following 16.

PMID:
18488825
18.

Genetically engineered T cells expressing a HER2-specific chimeric receptor mediate antigen-specific tumor regression.

Li S, Yang J, Urban FA, MacGregor JN, Hughes DP, Chang AE, McDonagh KT, Li Q.

Cancer Gene Ther. 2008 Jun;15(6):382-92. doi: 10.1038/cgt.2008.5. Epub 2008 Feb 22.

PMID:
18292797
19.

High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study.

Nash RA, McSweeney PA, Crofford LJ, Abidi M, Chen CS, Godwin JD, Gooley TA, Holmberg L, Henstorf G, LeMaistre CF, Mayes MD, McDonagh KT, McLaughlin B, Molitor JA, Nelson JL, Shulman H, Storb R, Viganego F, Wener MH, Seibold JR, Sullivan KM, Furst DE.

Blood. 2007 Aug 15;110(4):1388-96. Epub 2007 Apr 23.

20.

Executive dialogue series. Performance improvement in the era of quality improvement.

Brown L, Buckley J, Gibbs D, Kaplan G, Lofton K, McDonagh K, Schrader A, Vaughn A, Whetsell G, Wade R.

Hosp Health Netw. 2006 Nov;80(11):80-9. No abstract available.

PMID:
17216797
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk